Vertex Pharmaceuticals Incorporated - Common Stock (VRTX) stock analysis

VRTX · Vertex Pharmaceuticals Incorporated - Common Stock

Latest recorded price: USD 537.79

Model-estimated fair value: USD 326.76. This assumption-based estimate is for general research and is not investment advice.

Sector and industry: Healthcare · Biotechnology

At $537.79, VRTX trades 64.6% above the model's base-case value of $326.76. Using Operating FCFF DCF (revenue x margin - reinvestment), the model estimates $256.01 in the conservative case and $408.40 in the optimistic case, with a valuation confidence score of 55/100. About 72% of the value comes from the terminal value, so the result is sensitive to long-term growth and discount-rate assumptions. Fiscal 2025 figures: revenue growth 10.4%, free cash flow margin 26.6%, ROIC 19.6%. The model flags 1 risk signal for this company.

Similar companies in Healthcare